Multidisciplinary Alfred Psychiatry
research centre
Brain Stimulation Treatments
The Brain Stimulation Lab is at the forefront of transcranial magnetic stimulation (TMS) research in translational and therapeutic applications. TMS is a non-invasive brain stimulation technique that delivers electromagnetic energy to modulate brain activity and connectivity, and has been clinically proven to effectively and safely treat depression and other neuropsychiatric disorders.
​
Unlike pharmacological therapies, which are the treatment mainstays in depression, TMS has minimal side effects.
Under the leadership of psychiatrist and clinician-scientist Dr Leo Chen, the Brain Stimulation Lab focuses on translating cutting-edge neuroscience to large-scale, transformative clinical trials. This includes:
1) Clinical trials to improve the therapeutic efficacy of non-invasive therapeutic brain stimulation using pharmacological facilitation of synaptic neuroplasticity and signal transmission (i.e. making subtle and temporary changes in the biochemistry of the space where two brain cells connect to facilitate effective transmission of electrical signal from one brain cell to another), and;
2) Developing transdiagnostic treatment applications for therapeutic brain stimulation modalities by using neuroimaging biomarkers and causal networks to inform novel, individualised neurostimulation therapies. Establishing brain networks that have causal inference to the symptoms in question provides a wiring diagram which can be targeted and modulated using TMS in order to treat symptoms.
Some of their key projects include pharmacological augmentation to improve TMS’s antidepressant efficacy, a world-first proof-of-concept pilot study of TMS in Premenstrual Dysphoric Disorder (PMDD) and a collaboration with Harvard University in another world- first project using an MRI-derived brain target to treat anorexia nervosa.
​
Through their ongoing projects, the TMS Research Unit provides hundreds of patients access to innovative treatments via clinical trials, unlocking TMS for vulnerable community members who are currently in need of effective, innovative treatments.
Current Trials